Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen ...
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...
Thomas Smith’s rating is based on the promising developments and strategic positioning of Viridian Therapeutics. The company has reported favorable Phase 3 results for its lead asset ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback